Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PD1 & PDL1 inhibitors for mUC, where are we?

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, outlines efficacy and safety data on the use of PD1 & PDL1 inhibitors in the treatment of metastatic urothelial cancer (mUC) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.